Rodríguez-Lima DR et al., 2026-06-10: Systematic review and meta-analysis of nine randomized trials of methylene blue in circulatory shock, finding faster haemodynamic improvement but no significant mortality reduction. The best available synthesis of the "cytokine storm"/shock use.
MB was not associated with a statistically significant reduction in short-term mortality. Secondary analyses also did not demonstrate significant pooled effects for RRT, hospital length of stay, or ICU length of stay, although several individual trials reported faster hemodynamic improvement and reduced vasopressor exposure
Rodríguez-Lima DR et al., 2026-06-10: Systematic review and meta-analysis of nine randomized trials of methylene blue in circulatory shock, finding faster haemodynamic improvement but no significant mortality reduction. The best available synthesis of the "cytokine storm"/shock use. Study type: systematic review, meta-analysis and trial sequential analysis of RCTs (PROSPERO CRD420261326534). N=9 trials, 535 participants. Countries: multinational (mostly septic shock; one post-cardiac-surgery vasoplegia). MB dose/route per trial. Funding/conflicts: none declared. Comparator: standard therapy or placebo. Primary outcome 28-30-day mortality: no significant reduction; secondary outcomes (RRT, LOS) also null. Bearing CONTRADICTS the claim that MB prevents cytokine storm outcomes. Also filed as MTD-092, MTI-47 (claims C11, C16, C5). Study type: review.
